Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MISSION Therapeutics Strengthens Board

Published: Monday, October 01, 2012
Last Updated: Monday, October 01, 2012
Bookmark and Share
Appointments of Michael Moore and Fritz Frickel as Executive Chairman and Non-Executive Director respectively.

MISSION Therapeutics has announced the appointment of Dr Michael Moore as Executive Chairman and Fritz Frickel as Non-Executive Director.

Graziano Seghezzi of Sofinnova partners, on behalf of the investor syndicate, commented: “We warmly welcome Michael Moore and Fritz Frickel to the MISSION Board. Their combined commercial, drug translational and managerial experience will complement our existing capabilities and provide valuable links with the pharma and venture capital industries with which they have both enjoyed highly productive relationships”.

Dr Moore brings extensive experience to MISSION at a formative phase of the company’s development.

Following an earlier academic career principally at the Paterson Institute for Cancer Research (University of Manchester), Dr Moore has more than two decades of senior management experience in the biotechnology sector, as Chief Scientific Officer of Xenova Group plc and more recently as Chief Executive Officer of Piramed, the UK bioscience company acquired by F Hoffmann-La Roche in 2008.

Dr Moore also serves as a Non-Executive Director of several companies including PsiOxus Therapeutics. He is also a member of the Cancer Research UK Science Committee.

Dr Fritz Frickel joins the MISSION Board as a non-executive director. Currently an independent advisor to venture capital firms, biotech start-ups and universities, Dr Frickel was formerly Senior Vice-President of R&D and acting CEO of Alantos which was acquired by Amgen.

Other senior pharma roles have included SVP of research at Abbott, world-wide head of research at BASF and head of clinical, pharmaceutical and regulatory development at Knoll.

Dr Frickel served as non-executive director of RespiVert, an Imperial College spin-out, until its acquisition by Janssen Biotech Inc. in 2010 and is currently a director of new start-up company TopiVert.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MISSION Secures £20 million ($32 million) in Series B Financing
Pfizer Venture Investments join MISSION investor syndicate to advance compounds through preclinical development for genetically-defined cancers.
Tuesday, November 19, 2013
Biomedical Catalyst Feasibility Award to Tackle Drug-resistant Ovarian Cancer
Feasibility award granted by Technology Strategy Board to identify DUBs.
Tuesday, September 17, 2013
Appointment of Associate Faculty Member at Sanger Institute
MISSION Co-Founder and CSO, Professor Steve Jackson appointed as Faculty Member.
Monday, April 08, 2013
Scientific News
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Genes For Nose Shape Found
Genes that drive the shape of human noses have been identified by a UCL-led study.
Transcription Factor Isoforms Implicated in Colon Diseases
UC Riverside study explains how distribution of two forms of a transcription factor in the colon influence risk of disease.
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
NIH Funds New Studies on Ethical, Legal and Social Impact of Genomic Information
Four new grants from the National Institutes of Health will support research on the ethical, legal and social questions raised by advances in genomics research and the increasing availability of genomic information.
How Did The Giraffe Get Its Long Neck?
Clues about the evolution of the giraffe’s long neck have now been revealed by new genome sequencing.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!